Incelldx, Inc.

Amanda Noel Chargin

Keith Shults

Bruce K Patterson

Seyedhamed Jafarianmohamady

Fangfang Yin

Min Song

Srividyabhuvaneswari Subramaniam

Grace Elaine Knutson

Methods are provided for assaying neoplastic cells and/or neoplasia-related cells. Aspects of the methods involve detecting heterogeneity, per cell programmed-death ligand 1 (PD-L1) expression, and/or proliferation of neoplasia and/or neoplasia-related cells. Aspects of the methods include cytometrically assaying a labeled cell suspension to quantify per cell heterogeneity, per cell PD-L1 expression, proliferation, and/or other parameters to detect whether a neoplastic cell is present in the neoplasia sample. Aspects of the provided methods also include treating a subject based on the outcome of such an assay. In addition, kits that find use in practicing the subject methods are also provided.

Methods of assaying neoplastic and neoplasia-related cells and uses thereof

Methods are provided for assessing a cellular breast sample. Aspects of the methods include flow cytometrically obtaining sample data, cellular data, and combinations thereof, and then assessing the cellular breast sample based on the obtained data. In addition, compositions, e.g., kits, systems and programming, useful in practicing various embodiments of the methods are provided.

Methods of assessing cellular breast samples and compositions for use in practicing the same

Methods are provided for detecting the per cell programmed-death ligand 1 (PD-L1) expression of neoplasia cells. Aspects of the methods include cytometrically assaying a labeled cell suspension to quantify per cell PD-L1 expression to detect whether a neoplastic cell that expresses PD-L1 above a predetermined threshold is present in the neoplasia sample. In addition, kits that find use in practicing the subject methods are also provided.

Methods of detecting per cell PD-L1 expression and uses thereof

Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 are provided. Aspects of the methods include contacting a cellular sample with an HIV-1 inducing compound to produce an activated cellular sample; and assessing plasma viral load in the activated cellular sample to evaluate the cellular sample for latent cellular replication competent HIV-1. Also provided are devices and kits that find use in practicing the methods.

Growing community of inventors

San Jose, CA, United States of America

Amanda Noel Chargin